Company Interview / Pioneering psilocybin-assisted therapy for treatment-resistant depression

Key points:

Emyria's psilocybin-assisted therapy receives regulatory approval in AustraliaFacilities and specialists ready for the new treatment alongside existing MDMA programmeFinancial strategies and partnerships support accessibility and expansion plans

Dr Michael Winlo of Emyria states that the company has received approval to start a therapy programme for treatment-resistant depression. The programme uses psilocybin-assisted therapy, which is now legally available in Australia following the TGA's bold decision over a year ago. Michael emphasises its uniqueness and potential benefits for patients with limited options through standard treatments.

Emyria is ready to offer this new therapy from their bespoke facilities, thanks to an ethics endorsement from Act Health. They've trained 20 clinicians to provide this treatment alongside their existing MDMA programme for PTSD. Michael mentions a real demand for innovative treatments in mental health and is pleased to lead in using data to improve accessibility and affordability.

Michael highlights the transformational outcomes of psilocybin-assisted therapy. Unlike traditional medication, this therapy involves a few intensive sessions, and patients experience significant improvements. Emyria plans to expand their reach and maintain financial stability through clinical revenue and an anticipated R&D cash refund. The company collaborates with major payers, aiming to grow and increase the treatment's availability to benefit more patients.